Suspicious Ultrasound Characteristics Predict BRAFV600E-Positive Papillary Thyroid Carcinoma

被引:52
|
作者
Kabaker, Adam S. [1 ]
Tublin, Mitchell E. [2 ]
Nikiforov, Yuri E. [3 ]
Armstrong, Michaele J. [1 ]
Hodak, Steven P. [4 ]
Stang, Michael T. [1 ]
McCoy, Kelly L. [1 ]
Carty, Sally E. [1 ]
Yip, Linwah [1 ]
机构
[1] Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15213 USA
[2] Univ Pittsburgh, Dept Radiol, Pittsburgh, PA 15213 USA
[3] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15213 USA
[4] Univ Pittsburgh, Dept Endocrinol, Pittsburgh, PA 15213 USA
关键词
PREOPERATIVE ULTRASONOGRAPHY; SURGICAL-MANAGEMENT; BRAF MUTATION; NODULES; CANCER; RISK; MALIGNANCY;
D O I
10.1089/thy.2011.0274
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Current American Thyroid Association (ATA) guidelines recommend routine cervical ultrasound (US) in thyroid nodule evaluation. Specific US characteristics can help diagnose papillary thyroid carcinoma (PTC). The aim of this blinded cohort study was to determine whether these specific US characteristics can also reliably detect the more aggressive variants of PTC that are often associated with the BRAF(V600E) mutation. Methods: After Institutional Review Board approval, we identified a cohort of patients from January 2007 to December 2009 with histologic PTC 1 cm who had cervical US, initial thyroid surgery, and molecular testing for BRAF(V600E) on fine-needle aspiration biopsy or histology. Preoperative US images were evaluated by a single radiologist, who was blinded to BRAF status, for nodule size and the presence or absence of the following suspicious US features: taller-than-wide shape, ill-defined margins, hypoechogenicity, calcifications, noncystic composition, and absent halo. Results: BRAF-positivity was associated with most known suspicious US findings, including taller-than-wide shape (47% vs. 7%, p<0.001), ill-defined margins (42% vs. 9%, p<0.001), hypoechogenicity (83% vs. 36%, p<0.001), micro/macrocalcifications (87% vs. 24%, p<0.001), and absent halo (85% vs. 27%, p<0.001) but was not associated with noncystic composition. When 3 suspicious US features were present, BRAF-positivity was predicted with a positive predictive value of 82%. The absence of suspicious US features together with negative BRAF testing predicted PTC without extrathyroidal extension or lymph node metastasis (negative predictive value 88%). Conclusions: With routine preoperative cervical US and molecular testing, a trained radiologist or surgeon can improve the preoperative characterization of PTC, potentially impacting risk stratification and initial surgical management.
引用
收藏
页码:585 / 589
页数:5
相关论文
共 50 条
  • [41] Correlation of BRAFV600E mutation and clinical characteristics in coexistence of papillary thyroid carcinoma and Hashimoto's thyroiditis
    运新伟
    ChinaMedicalAbstracts(InternalMedicine), 2014, 31 (01) : 19 - 20
  • [42] Clinical implications of the extent of BRAFV600E alleles in patients with papillary thyroid carcinoma
    Liu, Lihua
    Chang, Jae Won
    Jung, Seung-Nam
    Park, Hee Sung
    Oh, Taejeong
    Lim, Young Chang
    Koo, Bon Seok
    ORAL ONCOLOGY, 2016, 62 : 72 - 77
  • [43] Clinical significance of the BRAFV600E mutation in multifocal papillary thyroid carcinoma in Korea
    Ahn, Hwa Young
    Chung, Yun Jae
    Kim, Byung Seup
    Kang, Kyung Ho
    Seok, Ju Won
    Kim, Hee Sung
    Park, Sung Jun
    Cho, Bo Youn
    SURGERY, 2014, 155 (04) : 689 - 695
  • [44] Retrospective study of BRAFV600E mutation and CT features of papillary thyroid carcinoma
    Hong, Xiaoquan
    Li, Juxiang
    Duan, Shaoyin
    You, Youkuang
    PEERJ, 2024, 12
  • [45] BRAFV600E Mutation Analysis in Papillary Thyroid Carcinoma: Is it Useful for all Patients?
    Ito, Yasuhiro
    Yoshida, Hiroshi
    Kihara, Minoru
    Kobayashi, Kaoru
    Miya, Akihiro
    Miyauchi, Akira
    WORLD JOURNAL OF SURGERY, 2014, 38 (03) : 679 - 687
  • [46] BRAFV600E Mutation Analysis in Papillary Thyroid Carcinoma: Is it Useful for all Patients?
    Yasuhiro Ito
    Hiroshi Yoshida
    Minoru Kihara
    Kaoru Kobayashi
    Akihiro Miya
    Akira Miyauchi
    World Journal of Surgery, 2014, 38 : 679 - 687
  • [47] The Primary Occurrence of BRAFV600E Is a Rare Clonal Event in Papillary Thyroid Carcinoma
    Guerra, Anna
    Sapio, Maria Rosaria
    Marotta, Vincenzo
    Campanile, Elisabetta
    Rossi, Stefania
    Forno, Irene
    Fugazzola, Laura
    Budillon, Alfredo
    Moccia, Tania
    Fenzi, Gianfranco
    Vitale, Mario
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (02): : 517 - 524
  • [48] The status of BRAFV600E mutation among Egyptian patients with papillary thyroid carcinoma
    El Tawil A.
    Mehaney D.
    Anis S.
    Salama A.
    Khattab H.
    El-Refaei S.
    Comparative Clinical Pathology, 2015, 24 (4) : 715 - 720
  • [49] Unfavorable efficacy to 131I ablation in BRAFV600E mutant papillary thyroid carcinoma with positive TgAb
    Zhang, Na
    Liang, Jun
    Lin, Yan-Song
    ONCOTARGET, 2017, 8 (57): : 97407 - 97415
  • [50] Use of bRAF/Mek Inhibitors to Enhance the Efficacy of Repeated Adjuvant RAI Therapy in Recurrent bRAFV600E-positive Papillary Thyroid Cancers s/p Reoperation
    Shen, D.
    Chan, H.
    Tsai, F.
    Chiu, Y.
    Liang, T.
    She, Y.
    Li, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S201 - S201